Danone (DN) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
20 Feb, 2026Executive summary
Achieved 4.5% like-for-like sales growth in FY 2025, with broad-based gains across all regions and categories, driven by positive volume/mix and disciplined execution.
Recurring operating margin improved by 44 basis points to 13.4%, with recurring EPS up 4.6% to €3.80, reflecting strong operational performance despite currency headwinds.
Free cash flow reached €2.8 billion, supporting disciplined capital allocation and shareholder returns.
Recognized for global sustainability leadership, including CDP Triple A and B Corp certification.
Portfolio transformation included increased stake in Australian dairy JV, now consolidated.
Financial highlights
FY 2025 sales: €27,283m, with reported growth stable due to significant negative currency impact; like-for-like sales growth of +4.5%.
Recurring operating income: €3,665m; recurring net income group share: €2,461m; EBITDA: €4,295m.
Free cash flow of €2.8 billion; dividend proposed at €2.25 per share, up 4.7%.
ROIC improved to 10.7%, up 62 bps year-over-year.
Working capital/sales ratio improved to -10.2%, best-in-class efficiency.
Outlook and guidance
2026 guidance: like-for-like sales growth expected between +3% and +5%, with recurring operating income to grow faster than sales.
Q1 2026 expected to see a one-off impact of 0.5%-1% of net sales from infant milk formula recalls, mainly in Europe and Middle East.
Confidence in normalization of supply and brand equity, with no major structural changes expected in regulation.
Latest events from Danone
- Targets 3–5% sales growth, €3bn cash flow, and double-digit ROIC, led by health and protein focus.DN
CME 20243 Feb 2026 - 4.0% LFL sales growth, margin up, cash flow +11%, 2024 guidance confirmed.DN
Q2 20242 Feb 2026 - Q3 2024 like-for-like sales up 4.2%, with all regions and categories contributing to growth.DN
Q3 202419 Jan 2026 - Achieved 4.3% LFL sales growth, margin gains, and record €3.0bn free cash flow in FY 2024.DN
Q4 20247 Jan 2026 - Q1 2025 sales rose 4.3% LFL, led by strong growth in China and confirmed 2025 guidance.DN
Q1 202521 Dec 2025 - 4.2% LFL sales growth, margin up 49 bps, and strategic acquisitions highlight H1 2025.DN
Q2 20254 Nov 2025 - Q3 2025 sales rose 4.8% LFL, driven by volume/mix and strong China, North Asia & Oceania growth.DN
Q3 202528 Oct 2025 - Agile structure, innovation, and targeted M&A drive growth in high protein and medical nutrition.DN
Barclays 18th Annual Global Consumer Staples Conference 202520 Oct 2025